CD19-CD22 CAR-T cells is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.

Coronavirus Disease 2019 (SARS-CoV-2) vaccine is under clinical development by Shionogi and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

The therapeutic candidate is under development for the treatment of ovarian cancer. It comprises of induced pluripotent stem (iPS) cell derived natural killer (iNK) cell.

COVID-19 (omicron JN.1) vaccine is under clinical development by Moderna and currently in Pre-Registration for Coronavirus Disease 2019 (COVID-19).

Flonoltinib maleate is under clinical development by Chengdu Zenitar Biomedical Technology and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

Anti-CDH17 CAR-T Cells is under clinical development by UTC Therapeutics and currently in Phase I for Pancreatic Cancer.

Biopharma and currently in Phase I for Metastatic Pancreatic Cancer. According to GlobalData, Phase I drugs for Metastatic Pancreatic Cancer have an 88% phase transition success rate (PTSR) indication ...

Alphaf-001 is under clinical development by Alpha Fusion and currently in Phase I for Follicular Thyroid Cancer.

Partnered Liquid Tumor-1 is under clinical development by Isogenica and currently in Phase I for Hematological Tumor.

Fosigotifator is under clinical development by Calico Life Sciences and currently in Phase II for Unspecified Central Nervous System Disorders.

ABX-002 is under clinical development by Autobahn Therapeutics and currently in Phase II for Major Depressive Disorder.